International Journal of Applied and Scientific Research (IJASR)
Vol. 4, No. 3, 2026: 153-160

Oral Insulin as a Future Therapeutic Strategy in Diabetes Management: Pharmaceutical Challenges and Translational Opportunities

Rehan Haider[1*], Zameer Ahmed[2], Hina Abbas[3], Shabana Naz Shah[4], Geetha Kumari Das[5], Sambreen Zameer[6]
[1]University of Karachi, Pakistan
[2]University of Health Sciences, Karachi, Pakistan
[3,6]Dow University of Health Sciences, Karachi, Pakistan
[4]SBB Dewan University, Karachi, Pakistan
[5]OPJS University, Rajasthan, India
Corresponding Author: Rehan Haider; rehan_haider64@yahoo.com

A R T I C L E I N F O

Keywords: Oral Insulin, Diabetes Mellitus, Drug Delivery Plans, Nanotechnology, Bioavailability, Drug Novelty

Received: 5 January
Revised: 23 February
Accepted: 23 March

A B S T R A C T

Insulin therapy remains the essential of diabetes management; still, its parenteral presidency presents challenges, including weak patient compliance, dose-related discomfort, and variable glycemic control. Oral insulin has long been deliberated as an ideal alternative, as it mimics the corporeal route of intravenous insulin delivery through the entryway distribution, conceivably reducing minor hyperinsulinemia and hypoglycemic risk. Despite these benefits, spoken insulin development has been obstructed by meaningful pharmaceutical impediments, including concerns with atom and molecule degradation in the gastrointestinal area and restricted stomach permeability. Recent advances in drug delivery learning, nanotechnology, and biomaterials have renewed interest in oral insulin as a possible healing alternative. Various strategies in the way that nanoparticle encapsulation, pertaining to the stomach coatings, substances causing chemicals to split into simpler substances, inhibitors, permeation enhancers, and mucoadhesive methods have illustrated hopeful results in preclinical and early clinical studies. These approaches aim to preserve insulin from stomachic depravity, enhance epithelial transport, and develop bioavailability. This item supports a narrative review of current research efforts concentrated on spoken insulin incidents, highlighting drug sciences, translational challenges, and dispassionate implications. While oral insulin is not currently accessible for routine dispassionate use, continued integrative research suggests the possibility authorize its future integration into diabetes administration, contributing to improved patient adherence and corporal insulin

DOI: https://doi.org/10.59890/ijasr.v4i3.209
E-ISSN: 3025-7670
https://nvlmultitechpublisher.my.id/index.php/ijasr/index

INTRODUCTION

Diabetes mellitus is a never-ending metabolic disorder from persistent hyperglycemia caused by inadequate insulin secretion, impaired insulin action, or a combination of the two. The worldwide prevalence of diabetes continues to rise, posing an important burden on healthcare systems and increasing the risk of enduring complications, to a heart failure, nephropathy, neuropathy, and retinopathy (1,2). Insulin therapy debris necessary for individuals accompanying type 1 diabetes and for many subjects accompanying advanced type 2 diabetes when spoken hypoglycemic agents fail to achieve glycemic control (3). Despite its dispassionate influence, conventional insulin medicine relies mainly on subcutaneous injections, which are associated with various disadvantages. Repeated injections can lead to weak patient devotion, needle fear, dose-site backlashes, and weakened quality of existence (4,5). Moreover, exogenous insulin administered via the subcutaneous route enters the systemic circulation directly, avoiding hepatic first-pass absorption. This non-physiological allocation grants permission to contribute to minor hyperinsulinemia, pressure gain, and a raised risk of hypoglycemia (6).

Oral insulin delivery has long been respected as an ideal alternative to injectable formulations due to its ability to mimic the natural route of insulin discharge. When administered verbally and consumed through the gastrointestinal area, insulin is transported directly to the liver by way of the portal vein, developing in preferential hepatic hydrogen organization and improved metabolic balance (7,8). Such a childbirth route commit enhance patient agreement, improve glycemic security, and reduce intrinsic antagonistic effects (9). However, the spoken presidency of insulin presents formidable drug and organic challenges. Insulin is a peptide hormone namely very naive to degradation by stomachic acid and proteolytic enzymes in the gastrointestinal area, including pepsin, trypsin, and chymotrypsin (10,11). In addition, insulin exhibits weak permeability across the stomach epithelium due to allure large molecular size and hydrophilic type, resulting in extremely depressed and variable bioavailability (12).

Advances in pharmaceutical sciences have revived interest in spoken insulin development. Innovative drug transmittal approaches, containing nanoparticle-based ships that carry airplanes, pertaining to the stomach coatings, something which incites activity inhibitors, absorption enhancers, and mucoadhesive schemes, have displayed promising results in keeping insulin from degradation and enhancing stomach assimilation in preclinical and early clinical studies (13–16). Nanotechnology-located transmittal systems, exceptionally, have arisen as a superior strategy on account of their ability to encapsulate insulin, upgrade strength, and facilitate transcellular or paracellular transport (17,18). Although various spoken insulin candidates have advanced into dispassionate tests, none have yet worked out regulatory approval, generally due to contradictory pharmacokinetic descriptions and insufficient bioavailability (19,20). Nevertheless, the resumed development of biomaterials, stomach transport biology, and expression erudition suggests that spoken insulin debris is a realistic general translational aim. This article reviews current research

efforts in spoken insulin delivery, focusing on drug development, translational challenges, and future opportunities in diabetes administration.

LITERATURE REVIEW

Early studies manifested that verbally administered insulin is promptly degraded by pertaining to stomach acid and proteolytic enzymes, resulting in negligible bioavailability. Subsequent research focused on securing transmission systems to overcome these impediments. Nanoparticle-located warships, containing polymeric and lipid nanoparticles, have shown reinforced strength and stomach uptake in exploratory models. Enteric-coated formulations and pH-susceptible polymers have further enhanced insulin protection in the gastrointestinal tract. Additionally, assimilation enhancers and something that incites activity have been examined to further epithelial transport. Although these plans have shown encouraging preclinical results, inconsistent effects remain inconsistent, emphasizing the need for revamped formulations and security judgment.

METHODOLOGY

This study adopts a narrative review design. Peer-reviewed items written between 2000 and 2025 were identified through photoelectric databases containing PubMed, Scopus, and Google Scholar. Keywords, to a degree, spoken insulin, insulin nanoparticles, and drug delivery methods were secondhand. Articles concentrating on formulation designs, pharmacokinetics, preclinical studies, and dispassionate tests were included. Non-English publications and different studies were forbidden.

Statistical Analysis

As this is a narrative review, no basic statistical experiment was conducted. Quantitative dossier stated in included studies was descriptively recapped, focusing on bioavailability percentages, glycemic effects, and pharmacokinetic parameters.

RESEARCH RESULT

The inspected studies signify that nanoparticle-located and mucoadhesive formulations supply the greatest augmentation in insulin support and assimilation. Bioavailability of spoken insulin formulations ranged from an inferior 1% to nearly 5% in advanced systems. Early-state dispassionate tests illustrated modest hydrogen-threatening belongings; however, buried individual instability waited for extreme conditions. Safety assessments mainly stated good gastrointestinal resistance, though the long-term security dossier was restricted.

Table 1. Pharmaceutical Strategies for Oral Insulin Delivery

Strategy	Mechanism of Action	Advantages	Limitations	Development Status
Nanoparticle encapsulation (polymeric, lipid-based)	Protects insulin from gastric degradation and enhances intestinal transport	Improved stability; targeted delivery; enhanced absorption	Low and variable bioavailability	Preclinical–early clinical
Enteric and pH-responsive coatings	Prevents insulin release in acidic stomach; releases in intestine	Protects insulin from acid degradation	Requires combination with permeation enhancers	Preclinical
Permeation enhancers	Transiently opens intestinal tight junctions	Improves epithelial permeability	Potential epithelial irritation	Preclinical–early clinical
Enzyme inhibitors	Reduces proteolytic degradation of insulin	Increases insulin survival	Long-term safety concerns	Experimental
Mucoadhesive systems	Prolongs residence time at absorption site	Increased contact time; improved uptake	Limited standalone efficacy	Preclinical

Table 2. Comparison of Injectable and Oral Insulin (Clinical and Pharmaceutical Perspective)

Parameter	Injectable Insulin	Oral Insulin (R&D Stage)
Route of administration	Subcutaneous injection	Oral
Patient compliance	Moderate to low	Potentially high
Physiological insulin pathway	Non-physiological (systemic first)	Mimics portal hepatic delivery
Bioavailability	High and predictable	Low and variable (<5%)
Risk of hypoglycemia	Moderate to high	Potentially reduced
Regulatory approval	Approved and established	Not yet approved
Innovation level	Conventional therapy	Formulation-driven pharmaceutical innovation



Figure 1. Barriers to Oral Insulin Delivery in the Gastrointestinal Tract



Figure 2. Mechanism of Oral Insulin Delivery Using Advanced Drug Delivery Systems

Figure 3. Translational Pathway of Oral Insulin Development



Figure 4. Oral Insulin as a Formulation-Driven Pharmaceutical Innovation

DISCUSSION

Oral insulin development shows a big drug challenge due to the complex physical obstacles of the gastrointestinal tract. While state-of-the-art delivery orders have manifested evidence-of-concept, realizing constant and certain pharmacokinetics remains the primary disadvantage. Regulatory instrumentalities demand reproducible bioavailability, dose sameness, and complete security, which current formulations have not yet completely obtained. Nonetheless, continued advances in nanotechnology, polymer science, and stomach physical science suggest the possibility of bridging this gap, putting spoken insulin as a future addition or alternative to injectable therapy.

CONCLUSIONS AND RECOMMENDATIONS

Although insulin therapy remains indispensable in diabetes management, reliance on injectable formulations is associated with persistent challenges related to patient adherence and non-physiological insulin distribution. This review discusses the current pharmaceutical strategies for enabling oral insulin delivery, including encapsulation within nanoparticles, enteric and pH-responsive systems, permeation enhancers, and mucoadhesive platforms, while emphasizing the pharmacokinetic and regulatory barriers limiting clinical translation so far. Although orally administered insulin formulations thus far exhibit low and variable bioavailability and are not yet suitable for routine clinical use, ongoing research has been establishing proof-of-concept for this approach. Oral insulin represents a formulation-driven pharmaceutical innovation applying advanced drug-delivery technologies in an effort to surmount historical limitations of injectable insulin therapy. Continued interdisciplinary research and carefully designed clinical studies aiming at the optimization of safety, reproducibility, and therapeutic efficacy may allow, in the future, the integration of oral insulin into diabetes care.

ADVANCED RESEARCH

This research still has limitations, so further research is needed on the topic of Oral Insulin as a Future Therapeutic Strategy in Diabetes Management: Pharmaceutical Challenges and Translational Opportunities to perfect this research and increase insight for readers.

ACKNOWLEDGMENT

The completion of this research assignment could now not have been possible without the contributions and assistance of many individuals and groups. We're. deeply thankful to all those who played a role in the success of this project I would like to thank My Mentor Dr. Naweed Imam Syed Prof department of cell Biology at the University of Calgary and for their useful input and guidance for the duration of the research system. Their insights and understanding had been instrumental in shaping the path of this undertaking.

REFERENCES

Bernkop-Schnürch A. Strategies to overcome impediments in spoken insulin. Adv Drug Deliv Rev. 2005.

Carino GP, Mathiowitz E. Oral insulin transfer. Adv Drug Deliv Rev. 1999.

Chen MC, and others. Chitosan-located spoken insulin. Biomaterials. 2011.

Damgé C, et al. Nanoparticle-located spoken insulin. Diabetes Metab. 2014.

Damgé C, Maincent P. Oral insulin during childbirth. J Control Release. 2008.

Fonte P, and others. Lipid-based nanoparticles for insulin transmittal. Int J Pharm. 2014.

Fonte P, and others. Oral insulin delivery: How far are we? J Diabetes Sci Technol. 2013.

Fonte P, et al. Polymeric shippers for insulin. J Biomed Nanotechnol. 2015.

Heinemann L. Alternatives to insulin needle. Diabetes Technol Ther. 2011.

Hompesch M, et al. Oral insulin dispassionate judgment. Diabetes Obes Metab. 2019.

Lee Y, and others. Clinical trials of spoken insulin. Diabetes Care. 2014.

Mahmood A, Bernkop-Schnürch A. Permeation enhancers. Adv Drug Deliv Rev. 2019.

Morishita M, Peppas NA. Is spoken insulin attainable? J Control Release. 2006.

Moroz E, Matoori S. Translational challenges of spoken insulin. Pharmaceutics. 2021.

Owens DR. Insulin preparations accompanying extended effect. Diabetes Technol Ther. 2011.

Patel A, and others. Challenges in spoken insulin transmittal. Drug Discov Today. 2012.

Pridgen EM, and others. Transepithelial transport of insulin. Sci Transl Med. 2013.

Rekha MR, Sharma CP. Oral transmittal of insulin. J Drug Target. 2013.

Rosenstock J, and others. Oral insulin tests. Lancet Diabetes Endocrinol. 2015.

Sarmento B, and others. Nanocarriers for insulin. Int J Nanomedicine. 2007.

Silva AC, and others. Mucoadhesive systems for insulin. Eur J Pharm Biopharm. 2012.

Sonaje K, and others. Oral insulin delivery methods. Adv Drug Deliv Rev. 2010.

Whitehead K, and others. Oral delivery of macromolecules. Nat Rev Drug Discov. 2008.

Wong CY, et al. Nanoparticle structures for spoken insulin. Adv Drug Deliv Rev. 2016.

Wong TW. Oral insulin transmittal. J Pharm Pharmacol. 2010.